Fexapotide Triflutate (NX-1207)

About Nymox Pharmaceutical

Nymox Pharmaceutical is dedicated to addressing significant unmet medical needs in urology, particularly in the large and growing market for BPH treatments. The company's proprietary drug candidate, fexapotide triflutate, represents a novel, minimally invasive approach that has demonstrated long-term efficacy and a favorable safety profile in clinical studies. Despite facing regulatory and financial challenges, Nymox continues to pursue the development and potential commercialization of its lead asset. The company's strategic direction hinges on securing regulatory approval and partnerships to bring its innovative therapy to market.

About Nymox Pharmaceutical

Nymox Pharmaceutical is dedicated to addressing significant unmet medical needs in urology, particularly in the large and growing market for BPH treatments. The company's proprietary drug candidate, fexapotide triflutate, represents a novel, minimally invasive approach that has demonstrated long-term efficacy and a favorable safety profile in clinical studies. Despite facing regulatory and financial challenges, Nymox continues to pursue the development and potential commercialization of its lead asset. The company's strategic direction hinges on securing regulatory approval and partnerships to bring its innovative therapy to market.

Therapeutic Areas

Other Benign Prostatic Hyperplasia (BPH) Drugs